- Home
- INTS vs MNDO Comparison
INTS vs MNDO Comparison
Compare INTS & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- MNDO
- Stock Information
- Founded
- INTS 2012
- MNDO 1995
- Country
- INTS United States
- MNDO Israel
- Employees
- INTS N/A
- MNDO N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- MNDO EDP Services
- Sector
- INTS Health Care
- MNDO Technology
- Exchange
- INTS Nasdaq
- MNDO Nasdaq
- Market Cap
- INTS 35.3M
- MNDO 40.8M
- IPO Year
- INTS 2023
- MNDO 2000
- Fundamental
- Price
- INTS $2.33
- MNDO $1.94
- Analyst Decision
- INTS Strong Buy
- MNDO
- Analyst Count
- INTS 3
- MNDO 0
- Target Price
- INTS $8.50
- MNDO N/A
- AVG Volume (30 Days)
- INTS 18.1K
- MNDO 55.9K
- Earning Date
- INTS 03-21-2025
- MNDO 03-04-2025
- Dividend Yield
- INTS N/A
- MNDO 11.40%
- EPS Growth
- INTS N/A
- MNDO N/A
- EPS
- INTS N/A
- MNDO 0.22
- Revenue
- INTS N/A
- MNDO $21,446,000.00
- Revenue This Year
- INTS N/A
- MNDO N/A
- Revenue Next Year
- INTS N/A
- MNDO N/A
- P/E Ratio
- INTS N/A
- MNDO $8.95
- Revenue Growth
- INTS N/A
- MNDO N/A
- 52 Week Low
- INTS $1.50
- MNDO $1.70
- 52 Week High
- INTS $5.78
- MNDO $2.28
- Technical
- Relative Strength Index (RSI)
- INTS 53.36
- MNDO 40.92
- Support Level
- INTS $2.17
- MNDO $1.87
- Resistance Level
- INTS $2.43
- MNDO $2.04
- Average True Range (ATR)
- INTS 0.20
- MNDO 0.05
- MACD
- INTS 0.01
- MNDO -0.01
- Stochastic Oscillator
- INTS 73.08
- MNDO 30.43
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets and implements real-time and off-line convergent billing and customer care software solutions. The company derives revenue from sale of software products and services in two operating segments namely Billing and Related Services, which derives key revenue and Messaging. The Company has three product lines: Product line A- billing and customer care solutions for service providers; Product line B - call accounting and call management solutions for enterprises; and Product line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in The Americas, Europe, Asia Pacific and Africa and Israel. It earns maximum revenue from Europe.